Grant Information
| Grant ID | CP130013 |
| Awarded On | February 19, 2014 |
| Title | Clinical Development and Commercialization of Oncolytic Adenovirus for Treating Malignant Glioma |
| Program | Product Development Research |
| Award Mechanism | Company Commercialization |
| Institution/Organization | DNAtrix, Inc. |
| Principal Investigator/Program Director | Frank Tufaro |
| Cancer Sites | Brain and Other Nervous System |
| Contracted Amount | $10813623 |
| Lay Summary |
DNAtrix, Inc. is a Texas-based companies developing modified viruses for the treatment of the most aggressive type of brain cancer called glioblastoma. Scientists have modified the common cold virus called adenovirus in 2 specific ways so that it can recognize and kill cancer cells very effectively without harming normal brain. The first product of its kind, called Delta-24-RGD, has just completed its first big test in more than 35 patients with GB at the MD Anderson Cancer Center in Houston. May patients with GB who participated had a remarkable response to the therapy, with evidence of tumor killing and improved survival. Perhaps equally important, there were no safety concerns or side-eff... |